A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Timothy F. Cloughesy, Andrew Brenner, John F. De Groot, Nicholas A. Butowski, Leor Zach, Jian L. Campian, Benjamin M. Ellingson, Laurence S. Freedman, Yael C. Cohen, Noa Lowenton-Spier, Tamar Rachmilewitz Minei, Shifra Fain Shmueli, Nicholas Avgeropoulos, Joseph Beck, Tara Benkers, Felix Bokstein, Andrew Brenner, Eric Burton, Jian Campian, Jose CarrilloJohn De Groot, Paula De Robles, Jan Drappatz, Irine Dunbar, Karen Fink, Morris Groves, Xiaosi Han, Hormigo Adila, Randy Jensen, Agnieszka Kowalska, Pyriya Kumthekar, Mijung Lee, Glenn Lesser, Alexander Lossos, Rimas Lukas, David Macdonald, Aaron Mammoser, Laszlo Mechtler, Nimish Mohile, Seema Nagpal, Garth Nicholas, Teri Kreisl, Edward Pan, Scott Peak, Michael Pearlman, James Perry, Richard Peterson, David Piccioni, Henry Robins, Lara Ronan, Michael Salacz, David Schiff, David Tran, Leor Zach, Tzahala Tzuk-Shina, Tobias Walbert, Patrick Y. Wen, Shlomit Youst

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Fingerprint

Medicine & Life Sciences